PANASONIC
26.10.2020 12:02:03 CET | Business Wire | Press release
Panasonic today announced that, in collaboration with the global contract research organization Texcell*1 , Texcell has verified the inhibitory effect of the nanoe™ X, technology with the benefits of hydroxyl radicals on the novel coronavirus (SARS-CoV-2).
nanoe™ X, the original ionizer to generate “nano-sized atomized water particles” is developed by Panasonic. It is an electrostatic atomization technology, that collects invisible moisture in the air and applies high voltage to it to produce “hydroxyl radicals contained in water”. The decisive factor is the existence of hydroxyl radicals inside nanoe™ X. Hydroxyl radicals are characterized by being strongly oxidative and highly reactive.
Panasonic has been conducting research on this technology since 1997, and has verified its effectiveness in a variety of areas, including inhibiting certain pathogenic microorganism (bacteria, fungi, and viruses) and allergens, breaking down PM 2.5 components that have adverse effects on the human body*2 .
In 2012, Panasonic conducted a virus clearance test with a third-party organization and confirmed the effectiveness of each of the four categories in terms of biological characteristics. Based on this result, Panasonic announced that "hydroxyl radicals contained in water" technology could be expected to have an inhibitory effect on new viruses*3 .
The novel coronavirus (SARS-CoV-2) of the current global pandemic is one such new type of virus and testing with Texcell has now confirmed that the nanoe™ X does have an inhibitory effect on this virus. This testing was carried out in a closed laboratory environment and was not designed to assess its efficacy in uncontrolled living spaces.
Panasonic will continue to pursue the potential of nanoe™ X technology to address possible risks associated with air pollution such as new pathogenic microorganisms, with the aim of creating cleaner environments for people around the world.
For reference :
Testing of inhibitory effect of nanoe™ X on the novel coronavirus (SARS-CoV-2)
・ Overview
A comparative verification was conducted in a 45L test space containing the novel coronavirus (SARS-CoV-2) with and without exposure to nanoe™ X.
・ Results
Over 99.99% of novel coronavirus (SARS-CoV-2) activity was inhibited within 2 hours.
Note: This verification was designed to generate basic research data on the effects of nanoe™ X on the novel coronavirus in laboratory conditions different from those found in living spaces. It was not designed to evaluate product performance.
・ Methodology and data
Organisation :Texcell
Subject :Novel coronavirus (SARS-CoV-2)
Device :nanoe™ X device
Method:
- nanoeTM
X device is installed at 15cm from the floor in the 45L test space.
- A piece of gauze saturated SARS-CoV-2 virus solution was placed in a petri dish and exposed to nanoeTM
X for a predetermined time.
- The virus infectious titer was measured and used to calculate the inhibition rate.
・ Results data
Test subject |
Inhibition rate* |
Capacity |
Hours |
SARS-CoV-2 |
99.99% |
45L |
2 hours |
Notes:
*1: Texcell is a global contract research organization that specializes in viral testings, viral clearance, immunoprofiling and R&D or GMP cell banking, for your R&D, GClP, GLP and GMP projects.
With more than 30 years of experience and roots within the Pasteur Institute in Paris, Texcell has a long recognized expertise in viral testing with a broad range of protocols for the detection of adventitious agents.
Texcell is the first spin-off of the Pasteur institute of Paris created in 1997.
*2: Main releases on verification cases
- May 12, 2009:Positive effects of charged water particles on viruses, bacteria, and agricultural chemicals have been verified.
- October 20, 2009: The new influenza virus inhibition effect of charged water particles has been verified.
- February 20, 2012:Suppression effect of charged water particles on pet-related allergens, bacteria, fungi, and viruses have been verified.
- January 16, 2014:Nano-sized electrostatic atomized water particles effectively breaks down PM2.5 components and inhibits growth of fungi attached to Yellow Sand.
*3: January 26, 2012: Virus suppression effect of charged water particles has been verified by the virus clearance test. Co-verified with Charles River Biopharmaceutical Services GmbH, a German testing organization.
About Panasonic
Panasonic is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th
anniversary in 2018, has expanded globally and now operates 528 subsidiaries and 72 associated companies worldwide, recording consolidated net sales of 7.49 trillion yen for the year ended March 31, 2020. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers.
https://www.panasonic.com/global
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005047/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release
A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
